Industry, innovation and social values

Science and Engineering Ethics

Volumn 11, Issue 1, 2005, Pages 31-40

  Bale Jr , Harvey E ^a  

^a Intl Fed Pharmaceutical M   (Switzerland)

Author keywords

Access; AIDS; Development; Innovation; Patents; Research

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MEDICAL RESEARCH; SOCIAL ASPECT;

EID: 13744250904     PISSN: 13533452     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11948-005-0053-9     Document Type: Conference Paper

References (57)

1. Commission on Macroeconomics and Health, Macroeconomics and health: Investing in health for economic development. CMH/WHO 2001, pp- 21-29.
2. Brower J., Chalk P. (2003) The global threat of new and re-emerging infectious diseases: reconciling US national security and public health policy. Rand Science and Technology 2003.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS), AIDS Epidemic Update: December 2003. UNAIDS 2003.
4. Reichert J.M., Milne Ch. P. (2000) Public good and private goods: the role of industry, academia, and government in drug discovery and development. Tufts Centre for the Study of Drug Development, 2000.
5. Henderson R., Cockburn I. (1993) Measuring competence? Exploring Firm Effects in Pharmaeutical Research. Strategic Management Journal, No. 15.
6. United Nations Development Program, Human Development Report 2001. UNDP 2001.
7. World Health Organisation, World Health Report 2003. Global Health: today's challenges. WHO 2003.
8. Satcher D. (1995) Emerging infections: getting ahead of the curve. Emerging Infectious Diseases, 1(1).
9. US Congress, January 2000.
10. Joint United Nations Programme on HIV/AIDS (UNAIDS), AIDS Epidemic Update: December 2003. UNAIDS 2003.
11. WHO, World Health Report 2003.
12. Will it reach on time? Emerging and re-emerging infectious diseases. United Nations Chronicle, Vol. 36, No. 1, 1999.
13. Malin A.S., McAdam K.P., Keith P.W. (1995) Escalating threat from tuberculosis: the third epidemic. Thorax, No. 50.
14. Antibiotic resistance - the interplay between antibiotic use in animals and human beings. Lancet Infectious Diseases, Vol. 3., January 2003.
15. Obaro S.K., Monteil M.A., Henderson D.C. (1996) The pneumococcal problem. British Medical Journal 312: 7145.
16. Zumla A., Grange J.M. (2001) Multidrug resistance tuberculosis - can the tide be turned? Lancet Infectious Diseases, Vol. 1.
17. Ridley R.G. (2002) Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415: 686-693.
18. Gallo R.C., Montagner L (2003) Débats et Opinions. Le Figaro, No. 18293, 2 June 2003.
19. WHO, World Health Report 2003.
20. Johnston M.I., Flores J. (2001) Progress in HIV vaccine development. Current Opinion in Pharmacology, 1: 504-510.
21. www.aidsmeds.com.
22. CASCADE Collaboration (2003) Determinants of Survival Following HIV-1 Seroconversion After the Introduction of HAART. The Lancet 362: 1267-1274.
23. PhRMA. Medicines in development for HIV/AIDS: 2003 Survey. PhRMA 2003.
24. Reichert J.M., Milne C.P. (2002) Public and private sector contributions to the discovery and development of 'impact' drugs. Tufts Centre for the Study of Drug Development, May 2002.
25. Van den Haak M.A., Vounatsos F.J.G., McAuslane J.A.N. (2002) International pharmaceutical R&D and sales 2001.CMR International, April 2002.
26. PhRMA, Pharmaceutical Industry Profile 2002. PhRMA, Washington DC, 2002.
27. The R&D revolution remains elusive. Scrip Magazine, February 2004.
28. Wang J. et al. (1999) Measuring country performance on health: Selected indicators for 115 countries. The World Bank, Human Development Network, Washington DC.
29. For example: NERA, The human and economic value of pharmaceutical innovation and opportunities for the NHS. A report for the ABPI. May 2004.
30. For example: Lichtenberg F.R. (2004) The expanding pharmaceutical arsenal in the war on cancer. National Bureau of Economic Research, Working Paper 10328, February 2004.
31. For example: Lichtenberg F.R. (1998) Pharmaceutical innovation, mortality reduction, and economic growth. National Bureau of Economic Research, Working Paper 6569, May 1998.
32. Milne G.M. (1998) Going Global: Healthcare Innovation.
33. The Boston Consulting Group (1993) The changing environment for US pharmaceuticals: the role of pharmaceutical companies in a systems approach to health care. Boston, April 1993.
34. The data for major vaccines such as measles, OPV3, BCG and DTP3. World Health Organisation, The World Health Report 1999.
35. UNDP, 2001.
36. Landau R., Achilladelis B., Scriabine A. (1999) Pharmaceutical innovation: Revolutionizing human health, Chemical Heritage Press, Philadelphia.
37. Gambardella A., Orsenigo L., Pammolli F. (2000) Global Competitiveness in Pharmaceuticals: A European Perspective. November 2000; http://www.efpia.org/ 3_press/figures260602.pdf.
38. DiMasi J. et al. (1991) Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10(2); Tufts Centre for the Study of Drug Development, 2001, available at http://csdd.tufts.edu/NewsEvents/RecentNews. asp?newsid=5
39. DiMasi J. et al. (1991) Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10(2); Tufts Centre for the Study of Drug Development, 2001, available at http://csdd.tufts.edu/NewsEvents/RecentNews. asp?newsid=5
40. Di Masi J.A., Hansen R.W. et al. (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics, Vol. 22.
41. IFPMA, Encouraging pharmaceutical innovation in developing countries, IFPMA 2002.
42. Mansfield, E, (1986), Patents and Innovation: An Empirical Study, Management Science (February) 173.
43. Mansfield E. (1993) Unauthorised use of intellectual Property: Effects on Investment, Technology Transfer and Innovation, in Global Dimensions of Intellectual Property Rights in Science and Technology, Eds. Wallerstein M, Mogee, M and Schoen R, National Academic Press, Washington DC, USA.
44. Klevorick A., Levin R., Nelson R., Winter S. (1987) Appropriating the returns from industrial research and development. Brookings Papers on Economic Activity, Vol. 3.
45. Morgan Stanley Dean Witter (1998) The new R&D paradigm: an investor guide - the Midas principle. September 1998.
46. IFPMA (2000) Encouragement of new clinical drug development: The role of data exclusivity. IFPMA.
47. Skillington G.L., Solovy E.M. (2002) The protection of test and other data required by Article 39.3 of the TRIPS Agreement. Northwestern Journal of International Law and Business, 24: 1.
48. Datamonitor (2002) Global generics guide. August 2002.
49. Commission on Macroeconomics and Health (2001) Macroeconomics and health: Investing in health for economic development. CMH/WHO 2001.
50. Kapstein E. B. (2001) The Corporate Ethics Crusade. Foreign Affairs 80: 105-119.
51. Leisinger K.M. (2002) The pharmaceutical industry and social responsibility: idealism without illusion and realism without resignation, Berlin, October 2002. See http://www.novartisfoundation.com/pdf/ novartis_social_responsibility.pdf.
52. 7,602 of the 10,375 drugs listed on the FDA's Orange Book have generic counterparts. See http://www.gphaonline.org/aboutgenerics/factsabout.html.
53. http://www.who.int/medicines/rationale.shtml.
54. Attaran A. (2004) How do patents and economic policies affect access to essential medicines in developing countries? Health Affaires 23 (3).
55. WHO (1999) Report on Infectious Diseases: Removing Obstacles to Healthy Development. WHO.
56. Buse K., Walt G. (2000) Global public-private partnerships: part I - a new development in health? Bulletin of the World Health Organisation, 78 (4).
57. IFPMA (2004) Building healthier societies through partnership. IFPMA May 2004.